Log In
BCIQ
Print this Print this
 

AlloCSC-01

  Manage Alerts
Collapse Summary General Information
Company TiGenix N.V.
DescriptionAdult allogeneic cardiac stem cells isolated from the right atrial appendages of donors and expanded in vitro
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPhase II
Standard IndicationMyocardial infarction (MI)
Indication DetailsTreat acute myocardial infarction (MI)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$319.6M

$1.3M

$312.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/30/2015

$319.6M

$1.3M

$312.3M

Get a free BioCentury trial today